Overview
The purpose of this study to evaluate the potential for disease-mediated drug-drug interactions between cendakimab and selected substrates of metabolic enzymes in eosinophilic esophagitis participants.
Principal investigator
Eligibility criteria
Inclusion Criteria:
- Active Eosinophilic esophagitis (EoE) with histologic evidence as a peak count of ≥ 15 eosinophils per higher-power field at any 2 levels of the esophagus
- Previously received an adequate trial of proton-pump inhibitor medication that did not provide complete response to EoE
- EoE symptoms documented in daily diary during the screening period
Exclusion Criteria:
- On a regimen of therapeutic anticoagulation
- Demonstrates evidence of immunosuppression or is receiving systemic immunosuppressive or immunomodulating drugs
- Currently receiving a high potency topical corticosteroid for dermatologic use
Other protocol-defined inclusion/exclusion criteria apply
Participate in this trial
Are you interested in enrolling in this study? Learn more here.
I'm Interested In ParticipatingFor Referring Providers
Do you have a patient you think would be a good candidate for this trial? Learn more about enrolling your patient.